Compare SIGA & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIGA | DBL |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 268.5M |
| IPO Year | 2016 | 2011 |
| Metric | SIGA | DBL |
|---|---|---|
| Price | $2.66 | $13.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 499.5K | 117.1K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | ★ 21.43% | 8.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $194.92 | N/A |
| P/E Ratio | $30.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $12.94 |
| 52 Week High | $7.11 | $15.56 |
| Indicator | SIGA | DBL |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 32.71 |
| Support Level | N/A | $12.94 |
| Resistance Level | $3.43 | $13.76 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 7.25 | 7.15 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.